Connect your AI

Profound Medical PROF Stock-Based Comp

Stock-Based Comp at other companies

Intuitive SurgicalISRG

$209.5M+13.1%

TriSalus Life Sciences, Inc.TLSI

$2.47M+52.6%

BioventusBVS

$3.26M+35.2%

Globus MedicalGMED

$12.62M-4.5%

Other financials

Income statement

Revenue$5.3M+104%

Gross profit$3.8M+107%

Operating income-$8.0M+28.2%

Net income-$7.1M+34.2%

EPS (diluted)$0.19-47.2%

Balance sheet

Cash & equivalents$50.3M+8.3%

Total debt$7.5M+52.8%

Total equity$59.4M+17.0%

Total assets$73.5M+20.7%

Cash flow

Operating cash flow-$8.6M-3.6%

CapEx$44.0K—

Free cash flow-$9.6M—

Valuation

Market cap$241.65M+33.9%

Enterprise value$198.81M+32.5%

P/S12.8×-2.4×

Profitability

Gross margin71.1%+3.4pp

Operating margin-202.6%-51.3pp

Net margin-206.8%-39.0pp

FCF margin-238.4%—

Returns & leverage

Return on equity-70.6%+4.8pp

Debt / equity0.1×0.0×

Current ratio6.6×-4.8×

Where this comes from

Reported directly by Profound Medical in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Profound Medical’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Profound Medical's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Profound Medical's stock-based comp?: Profound Medical (PROF) reported stock-based comp of $1.05M in Q1 2026.
How has Profound Medical's stock-based comp changed year-over-year?: Profound Medical's stock-based comp increased by 6.0% year-over-year, from $989K to $1.05M.
What is the long-term trend for Profound Medical's stock-based comp?: Over 2 years (2023 to 2025), Profound Medical's stock-based comp has grown at a 26.8% compound annual growth rate (CAGR), from $3.42M to $5.49M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.